FECH

FECH (ferrochelatase) catalyzes the terminal step of heme biosynthesis, the insertion of iron into protoporphyrin IX (PpIX), and its loss or inhibition causes PpIX accumulation with downstream cell-death consequences (PMID:35697292, PMID:39409147). Expression of FECH is controlled at multiple levels: transcriptionally, c-Myc translocates to the nucleus, binds Max, and occupies E-boxes in the FECH promoter (outside CpG islands) to drive transcription in erythroid cells, a process modulated by promoter methylation (PMID:21903580); post-transcriptionally, the intronic IVS3-48T/C (c.315-48T>C) variant increases use of a constitutive aberrant acceptor splice site, and the mis-spliced transcript is degraded by nonsense-mediated decay, dose-dependently lowering steady-state FECH and producing the enzyme deficiency required for erythropoietic protoporphyria (EPP) (PMID:11753383, PMID:29941360). Additional pathogenic alleles act through allele-specific transcript loss (a promoter/exon-1 deletion) or a deep-intronic methylation-dependent pseudo-exon insertion, converging on the same outcome of reduced functional FECH (PMID:17888693, PMID:31273344). Enzymatically, FECH activity is positioned downstream of Ras/MEK signaling via HIF-1α, such that pathway inhibition lowers FECH activity and raises PpIX (PMID:33335181). Pharmacological FECH inhibition blocks PpIX-to-heme conversion and, when combined with HMOX1 upregulation, drives iron overload and ferroptosis in cancer cells (PMID:35697292).

1. 2001 High

   Established why a low-penetrance intronic polymorphism, rather than a coding mutation, is required for EPP phenotype expression by defining a post-transcriptional mechanism that lowers FECH dosage.

   Evidence Haplotype segregation analysis with molecular characterization of aberrant splicing and NMD in EPP families

   PMID:11753383

   Open questions at the time

   • Does not quantify the absolute fraction of mis-spliced transcript needed to cross the pathological threshold
   • Mechanism of how the SNP biases splice-site choice not resolved at the spliceosome level
2. 2007 Medium

   Showed that large structural deletions removing the promoter and exon 1 abolish transcription from the affected allele, defining an allele-loss route to FECH haploinsufficiency.

   Evidence Long-PCR breakpoint mapping plus RNA analysis demonstrating absent transcript from the deleted allele

   PMID:17888693

   Open questions at the time

   • Single family/lab observation
   • Does not address whether residual allele expression is itself modulated by trans factors
3. 2011 Medium

   Identified the transcriptional driver of FECH in erythroid cells, linking promoter methylation status to c-Myc/Max E-box occupancy and heme output.

   Evidence Promoter E-box mapping, methylation analysis, c-Myc/Max ChIP and nuclear translocation imaging in murine erythroid leukemia cells and erythroblasts

   PMID:21903580

   Open questions at the time

   • Single lab
   • Direct demonstration in human erythroid cells not shown
   • Quantitative contribution of c-Myc relative to other promoter factors unclear
4. 2018 Medium

   Resolved whether the IVS3-48T/C variant is merely a modifier or independently pathogenic by quantifying aberrant splicing across genotypes.

   Evidence Digital PCR absolute quantification of aberrant and total FECH mRNA in a genotype-stratified cohort

   PMID:29941360

   Open questions at the time

   • Single lab
   • Does not link transcript-level changes to enzyme activity measurements in the same individuals
5. 2019 Medium

   Extended the mutational spectrum by showing a deep-intronic variant can act through a methylation-dependent pseudo-exon insertion, coupling DNA methylation to aberrant splicing.

   Evidence High-throughput resequencing with qualitative RNA analysis and quantitative DNA methylation assays

   PMID:31273344

   Open questions at the time

   • Single lab
   • Causal contribution of the new CpG methylation versus the silencer loss not fully separated
6. 2020 Medium

   Placed FECH enzymatic activity within oncogenic signaling by showing HIF-1α operates downstream of MEK to control FECH and PpIX levels.

   Evidence MEK and HIF-1α inhibition in RasV12-transformed cells and transgenic mice with PpIX accumulation assays

   PMID:33335181

   Open questions at the time

   • Single lab
   • Whether HIF-1α regulates FECH transcription, translation, or activity directly not distinguished
7. 2022 Medium

   Demonstrated FECH as a druggable enzymatic target whose inhibition, combined with HMOX1 upregulation, drives ferroptotic cell death in cancer.

   Evidence Thermal proteome profiling to identify FECH as the DMC target, enzymatic activity assay, and knockdown/overexpression in cancer cells

   PMID:35697292

   Open questions at the time

   • Single lab
   • DMC selectivity for FECH versus other heme-pathway enzymes not exhaustively excluded
8. 2024 Medium

   Defined the in vivo loss-of-function phenotype of FECH, linking PpIX accumulation to intrinsic apoptosis and altered myeloid output, and showed pharmacological rescue.

   Evidence CRISPR/Cas9 fech knockout zebrafish with apoptosis, PpIX fluorescence, and immune-cell readouts plus UDCA treatment

   PMID:39409147

   Open questions at the time

   • Single lab
   • Mechanism by which UDCA reduces PpIX and apoptosis not defined
   • Relationship between apoptosis here and ferroptosis reported in cancer models unresolved
9. 2021 Low

   Implicated an upstream MEK-ERK regulator (IGHG1) in controlling FECH expression in colorectal cancer.

   Evidence shRNA knockdown of IGHG1 with western blot for pERK and FECH and PpIX/hemin quantification

   PMID:34553073

   Open questions at the time

   • Indirect pathway placement via upstream knockdown with no direct FECH mechanistic assay
   • Single lab
   • Does not establish whether IGHG1 acts transcriptionally or post-transcriptionally on FECH

• How the multiple regulatory inputs (c-Myc transcription, splicing/NMD dosage control, HIF-1α/MEK signaling) are integrated to set FECH activity in a given cell type, and the structural basis of iron insertion, remain unresolved in this corpus.
• No structural/catalytic mechanism of iron insertion characterized in the timeline
• Cross-talk between transcriptional and splicing regulation not integrated
• Whether ferroptosis versus apoptosis dominates upon FECH loss is context-dependent and unresolved